51st week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210393610 | COMPOSITIONS AND METHODS FOR TREATING GOUT AND HYPERURICEMIA - The present disclosure relates to the joint use of Compound A and Compound B in the preparation of medications for the treatment of gout or hyperuricemia. Specifically, Compound A is the compound of Formula I, a pharmaceutical salt thereof, or an ester thereof, and Compound B is allopurinol or febuxostat. In particular, a method for treating gout or hyperuricemia in which the compound of Formula I-1 works in conjunction with febuxostat shows a good treatment effect. | 2021-12-23 |
20210393611 | LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAME - Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage. | 2021-12-23 |
20210393612 | POLYMORPHIC COMPOUNDS AND USES THEREOF - The present invention relates to free-base and salt forms, and compositions thereof of small molecule therapeutics acting as a scavenger for toxic aldehydes. The present invention further relates to use of the free-base and salt forms, and compositions thereof for treating diseases, disorders, or conditions in which aldehyde toxicity is implicated in their pathogenesis. | 2021-12-23 |
20210393613 | TOPICAL MONTELUKAST FORMULATIONS - The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water. | 2021-12-23 |
20210393614 | QUINONE REDUCTASE 2 INHIBITORS FOR USE AS NEUROPROTECTIVE AGENTS - Provided herein according to some embodiments is a method of treating acute neural injury in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Also provided is a method of treating vascular dementia in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Further provided is a method of treating CNS lupus in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. | 2021-12-23 |
20210393615 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND EXPOSURE TO NERVE AGENTS - Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABA | 2021-12-23 |
20210393616 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHOSIS - The present invention refers to a novel medical use of the (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-3-methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]naphthyridine compound [CAS-186002-54-0], known in the literature under code RS-79948-197, i.e., to its use in the treatment of psychoses. In particular, the present invention refers to the RS-79948-197 compound as an atypical antipsychotic for use in the treatment of psychoses, in particular of schizophrenia. Furthermore, the present invention refers to a pharmaceutical composition comprising the RS-79948-197 compound for use in the treatment of psychoses, in particular of schizophrenia. | 2021-12-23 |
20210393617 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) - The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, most preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer. | 2021-12-23 |
20210393618 | BUPRENORPHINE TO TREAT RESPIRATORY DEPRESSION - The disclosure provides methods for treating, preventing, and reducing the incidence of opioid-induced respiratory depression, opioid-induced apnea, and opioid overdose in patients by administering buprenorphine or a pharmaceutically acceptable salt thereof. | 2021-12-23 |
20210393619 | VAGINAL GEL - A composition having gel-like consistency contains metronidazole, terconazole, a physiologically acceptable thickener and water. The composition is useful for treating bacterial vaginosis as well as vulvovaginal candidiasis. | 2021-12-23 |
20210393620 | Methods of Treatment of Cancer Comprising CDC7 Inhibitors - Herein disclosed are methods of treatment administering SRA141 as a monotherapy or in a combination therapy useful for inhibiting the growth of tumors such as those in patients with cancer. | 2021-12-23 |
20210393621 | COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA - A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided. | 2021-12-23 |
20210393622 | METHODS FOR ADMINISTERING CORTICOSTEROIDS - Provided is a method for administering a corticosteroid to a patient in need thereof, comprising: determining a target threshold for the ratio of urinary (tetrahydrocortisol+allotetrahydrocortisol) to urinary tetrahydrocortisone for the patient; and administering an HSD1 inhibitor to the patient. Also provided is a method for reducing or preventing the side effects associated with corticosteroid administration to a patient in need thereof, comprising: determining a target threshold for the ratio of urinary (tetrahydrocortisol+allotetrahydrocortisol) to urinary tetrahydrocortisone for the patient; and administering an HSD1 inhibitor to the patient. | 2021-12-23 |
20210393623 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors - The present invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, the present invention provides a pharmaceutical composition comprising the said compound. | 2021-12-23 |
20210393624 | PROCESS FOR PRODUCING PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY - The invention relates to a process for producing pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and to the use of the dosage forms obtained by the said production process to treat and/or prevent breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring. | 2021-12-23 |
20210393625 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) - This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan. | 2021-12-23 |
20210393626 | Pharmaceutical Composition Comprising PARP Inhibitors - A solid dispersion for PARP inhibitors, comprising a compound represented by formula I and a carrier material, wherein the carrier material comprises polyvinylpyrrolidone. A pharmaceutical composition, comprising a solid dispersion, a filler, a disintegrating agent and a lubricant. A preparation method for the solid dispersion. Use of the solid dispersion or the pharmaceutical composition in the preparation of drugs for treating cancers. | 2021-12-23 |
20210393627 | MEDICAL APPLICATION OF PYRIMIDINE SULFONAMIDES DERIVATIVES - The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above. | 2021-12-23 |
20210393628 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION - This invention is in the field of medicinal chemistry. In particular, provided herein are compositions and methods for preventing or reversing T cell exhaustion. In certain embodiments, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to a new class of small-molecules having a thiazole, imidazolepyridiazine or piperazinyl-methyl-aniline structure, or by expanding genetically engineered T cells in the presence of such small molecules. | 2021-12-23 |
20210393629 | FORMULATIONS OF INFLUENZA THERAPEUTICS - Provided herein are compositions of an antiviral therapeutic to treat influenza suitable for administration via inhalation. | 2021-12-23 |
20210393630 | ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER - The present invention discloses an adjuvant treatment of node-positive, early stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer comprising administering an effective amount of an endocrine therapy in combination with an effective amount of abemaciclib or a pharmaceutically acceptable salt thereof. | 2021-12-23 |
20210393631 | INTEGRASE INHIBITORS FOR THE PREVENTION OF HIV - The present invention provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of bictegravir, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided. | 2021-12-23 |
20210393632 | EGFR INHIBITORS FOR TREATING KERATODERMAS - Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques. The inventors obtained remarkable results with a treatment with a EGFR inhibitor (e.g. erlotinib) in 3 patients with Olmsted Syndrome and erythemalgia linked to different TRPV3 mutations. In less than 3 months, the drug induced a complete disappearance of the hyperkeratosis and the pain. Anorexia and insomnia disappeared with an improvement of the growth. Accordingly, the present invention relates to the use of EGFR inhibitors for the keratodermas. | 2021-12-23 |
20210393633 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: | 2021-12-23 |
20210393634 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT - The present invention provides a prophylactic and/or therapeutic agent for inflammatory disease including a compound or a salt thereof, or a solvate thereof, the compound represented by a formula (1): | 2021-12-23 |
20210393635 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS - The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc. | 2021-12-23 |
20210393636 | TREATMENT OF CNS AND DEVELOPMENTAL DISORDERS USING HIGH DOSE 5-FORMYL-(6S)-TETRAHYDROFOLATE - Methods for treating developmental or chronic cerebral nervous system disorders using 5-formyl-(6S)-tetrahydrofolate and pharmaceutically acceptable dosage forms therefor are provided. | 2021-12-23 |
20210393637 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS - The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided. | 2021-12-23 |
20210393638 | NOVEL FORMULATION AND TREATMENT METHODS - The invention relates to pharmaceutical compositions comprising 6-thioguanidine (6-TG) wherein the composition is formulated for release of 6-TG in the distal intestine. Methods for treating a disease or condition of the distal ileum that responds to 6-TG wherein the 6-TG is released in the distal intestine are also disclosed. | 2021-12-23 |
20210393639 | VASOACTIVE TOPICAL COMPOUND TO AFFECT TISSUE BLOOD FLOW, REDUCE TISSUE NECROSIS AND PROMOTE HEALING - The present disclosure relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. In a preferred embodiment, the compositions comprise a phosphodiesterase inhibitor, a calcium channel blocker, a nitric oxide producer, and an α-adrenergic antagonist. Methods of making the compositions and using the compositions are also disclosed. | 2021-12-23 |
20210393640 | MEDICAMENT FOR THE TREATMENT OF CHRONIC COUGH - Provided is a pharmaceutical composition for treating chronic cough, which has substantially no side effects of taste disturbance. | 2021-12-23 |
20210393641 | THERAPEUTIC COMPOUNDS AND USES THEREOF - Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided. | 2021-12-23 |
20210393642 | COMPOSITION FOR PREVENTING OR TREATING SJOGREN'S SYNDROME - Provided is a composition for preventing or treating Sjogren's syndrome. A composition for preventing or treating Sjogren's syndrome includes a compound represented by a specific chemical formula, or a pharmaceutically acceptable salt thereof, and has the effect of preventing or treating Sjogren's syndrome. | 2021-12-23 |
20210393643 | Protection of Cells from Degeneration and Treatment of Geographic Atrophy - Therapeutic uses P2X | 2021-12-23 |
20210393644 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament - Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A | 2021-12-23 |
20210393645 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS - In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neurological disease is multiple sclerosis (also referred to as “MS”). | 2021-12-23 |
20210393646 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF L-DOPA-INDUCED DYSKINESIA - Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA. | 2021-12-23 |
20210393647 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF - The present invention provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception. | 2021-12-23 |
20210393648 | METHODS AND COMPOSITIONS FOR REDUCING BODY FAT AND ADIPOCYTES - Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): | 2021-12-23 |
20210393649 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS - Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. | 2021-12-23 |
20210393650 | Designing Treatments for Chemotherapy-Induced and Age-Related Menopausal Symptoms Using Combinations of Natural Products and Prescription Medications - The present invention provides methods for alleviating menopausal symptoms as a result of chemotherapy-induced or natural menopause in a subject, the method comprising administering an effective amount of a natural product or combination of natural products tailored to a subjects specific symptoms, with an effective amount of hormonal or non-hormonal synthetic prescription medication. In particular embodiments, the natural product or combination of natural products alleviate vasomotor menopausal symptoms in a subject, while the prescription medication alleviates symptoms associated with genitourinary syndrome of menopause. In some embodiments, the natural product or combination of natural products is prepared in formulations designed for administration at different times of day. | 2021-12-23 |
20210393651 | TARGETING THE ONCOGENIC TRANSCRIPTION FACTOR STAT5 WITH MINERALOCORTICOID ANALOGUES - The present invention relates to compositions and methods for treating cancer with targeted mineralocorticoid analogues | 2021-12-23 |
20210393652 | PROSTATE CANCER TREATMENT VIA SYNERGISTIC INHIBITION OF ARYL HYDROCARBON RECEPTOR (AHR) AND SRC - Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed. | 2021-12-23 |
20210393653 | REMDESIVIR TREATMENT METHODS - Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof. | 2021-12-23 |
20210393654 | TRIAZOLE BISPHOSPHONATE GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITORS - Disclosed herein are inhibitors of the GGDPS enzyme, and methods for their use in treating or preventing diseases, such as multiple myeloma. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: | 2021-12-23 |
20210393655 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint - The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention. | 2021-12-23 |
20210393656 | A PROCESS FOR PREPARATION OF A STABLE PHARMACEUTICAL COMPOSITION OF BORTEZOMIB - The present invention relates to a process for preparation of a stable pharmaceutical composition of Bortezomib. The said pharmaceutical composition of Bortezomib provides an improved stability compared to the reconstituted solution of the lyophilized product. | 2021-12-23 |
20210393657 | SYNTHETIC COMPOSITION FOR PREVENTING OR TREATING CVD - A method for reducing the likelihood of a non-infant human experiencing a cardiovascular disease (CVD) associated with hypercholesterolemia, hypertension, or a metabolic disorder such as type II diabetes and/or insulin resistance. Various examples of the method include selecting an amount of one to five human milk oligosaccharides (HMOs) selected from the fucosylated HMOs 2′-fucosyllatcose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), and lacto-N-fucopentaose I (LNFP-I) and the non-fucosylated neutral HMOs lacto-N-tetraose and lacto-N-neotetraose that is effective for increasing the relative abundance of | 2021-12-23 |
20210393658 | METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTH - The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to improve the health, nutrition, and growth performance. The present disclosure further relates to methods of modulating the microbial species present in the gastrointestinal tract of an animal. Such modulation includes, for example, modulating the level or function of microbial species. | 2021-12-23 |
20210393659 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS - Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: | 2021-12-23 |
20210393660 | METHOD OF TREATING CANCER - There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more. | 2021-12-23 |
20210393661 | SMALL MOLECULE-MEDIATED RESTORATION OF AIRWAY SURFACE PHYSIOLOGY IN HUMAN CYSTIC FIBROSIS LUNG EPITHELIA - Provided herein are complexes comprising amphotericin B (AmB) or derivatives and sterols. Also provided herein are methods of treating cystic fibrosis using AmB or complexes comprising AmB or derivatives and sterols. | 2021-12-23 |
20210393662 | USE OF SGLT2 INHIBITORS TO TREAT PRIMARY SCLEROSING CHOLANGITIS - The invention relates to the use of pharmaceutical compositions of the SGLT2 inhibitor, remogliflozin etabonate, to treat primary sclerosing cholangitis (PSC). Methods and compositions associated with the invention can improve or maintain clinical outcomes of PSC symptoms, such as ascites accumulation, hepatic encephalopathy, development of varices, jaundice, variceal bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer. | 2021-12-23 |
20210393663 | PHARMACEUTICAL FORMULATION CONTAINING ACTIVE METABOLITES OF REMDESIVIR OR ITS ANALOG FOR INHALATION - The present invention relates to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) an active substance selected from the group consisting of alanine metabolite, nucleoside monophosphate, nucleoside triphosphate, and GS-441524; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer. | 2021-12-23 |
20210393664 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA USING DEVIMISTAT - The invention provides methods, compositions, and medical kits for treating acute myeloid leukemia using devimistat in combination with cytarabine and mitoxantrone. | 2021-12-23 |
20210393665 | LOW-INTENSITY TREATMENT OF HEMATOLOGICAL DISORDERS - The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine. | 2021-12-23 |
20210393666 | METHODS AND COMPOSITIONS FOR TREATING ORAL MUCOSITIS - Methods and pharmaceutical compositions including Bisphosphocins for treating oral mucositis in a patient are disclosed. | 2021-12-23 |
20210393667 | TARGET FOR ANTI-CANCER THERAPY - The present invention relates to a composition and uses thereof. The invention relates to a composition for use in stimulating neoantigen production in a cancerous tumour. In particular, the composition comprises a compound or a pharmaceutically acceptable salt thereof, wherein the composition is a negative modulator of the expression, function or stability of ribonucleotide reductase. | 2021-12-23 |
20210393668 | USE OF OLIGONUCLEOTIDES FOR THE TREATMENT OF TUMORS - In a method of treating a patient having a solid tumor, the solid tumor is completely or partially resected or ablated and then a therapeutically-effective amount of an oligonucleotide that kills tumor cells is applied or administered in a body cavity created by the resection or ablation in order to kill tumor cells remaining in, or in the surroundings of, a tumor bed and/or to suppress metastases. Thus, the oligonucleotide counteracts the development of recurrences of the solid tumor or new metastases. The oligonucleotide may act, e.g., in a pleiotropic manner in at least one type of tumor cell. | 2021-12-23 |
20210393669 | METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA - The present disclosure provides using a double-stranded oligonucleotide compound as a novel therapy to improve the quality of life and joint function of patients with hemophilia A and hemophilia B. | 2021-12-23 |
20210393670 | INHIBITION OF EXPANSION AND FUNCTION OF PATHOGENIC AGE-ASSOCIATED B CELLS AND USE FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE - This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders. | 2021-12-23 |
20210393671 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME - The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof. | 2021-12-23 |
20210393672 | BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS - The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided. | 2021-12-23 |
20210393673 | SYNTHETIC MELANIN NANOPARTICLES AND USES THEREOF - Provided, inter alia, are synthetic melanin nanoparticles (MelNPs) useful for protecting keratinocytes from UV-damage and for treating melanin-defective diseases. | 2021-12-23 |
20210393674 | OZONOLYSIS FOR ACTIVATION OF COMPOUNDS AND DEGRADATION OF OZONE - Provided is an inactive compound that is activated by reaction with ozone into an active compound having a carbonyl oxygen. Also provided is a method of activating the above inactive compounds. Further provided is a method of treating a disease or condition in a subject using the above compound at a site that is not exposed to atmospheric ozone. Additionally provided is a method of determining internal ozonolysis in a subject using the above compound. Also provided is a molecule less than 1000 mw, having a double bond that is reactive with ozone, and forms a nontoxic compound after reacting with ozone. Further provided is a method of degrading ozone. | 2021-12-23 |
20210393675 | FORMULATION COMPRISING OZONISED OIL IN THE TREATMENT OF A TUMOUR - A formulation including at least one ozonized oil for use in the prevention and/or treatment of a tumour, preferably a malignant tumour is described. The formulation is for use by administration chosen from oral, topical, by injection, and combinations thereof. The tumour is chosen from a solid tumour; a cutaneous tumour; a mucosal tumour; and a liquid tumour. | 2021-12-23 |
20210393676 | APPLICATION OF HONOKIOL IN ANTI-OTOTOXICITY AND HEARING PROTECTION - Disclosed are methods and pharmaceutical compositions for treating and/or preventing hearing loss in a subject in need thereof. The disclosed methods typically utilize and the pharmaceutical compositions typical comprise an effective amount of a polyphenol therapeutic agent such as honokiol. | 2021-12-23 |
20210393677 | COMPOUNDS FOR MODULATION AND AS FUNCTIONAL REPLACEMENT OF ALPHAKETOGLUTARIC ACID (2OG)-DEPENDENT OXYGENASES - The present invention relates to an alternative co-substrate of ketoglutaric acid-dependent dioxygenases for functional production and control of same, with the aim of achieving therapeutic effects against cancer, neurodegenerative diseases and age related diseases. Epigenetically induced diseases caused by dysregulation and in particular also by metabolic dysfunction in the citric acid cycle are likewise targeted by this therapy. | 2021-12-23 |
20210393678 | PERSONALIZED FOOD PRODUCTS FOR ENSURING ADEQUATE IRON INTAKE - The present invention relates to methods for treating iron deficiency in a subject comprising noninvasively determining the hemoglobin level in the subject, and providing the subject with an iron supplement accordingly. | 2021-12-23 |
20210393679 | FORMULATION, USE AND METHOD FOR BROAD-SPECTRUM PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS CAUSED BY SARS-CoV-2 AND OTHER EMERGING VIRUSES | 2021-12-23 |
20210393680 | USE OF AN ANTIMICROBIAL COMPOSITION - The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: | 2021-12-23 |
20210393681 | Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity - Disclosed are means, methods, and compositions of matter for prophylaxis and/or treatment of SARS-CoV-2 by administration of dendritic cells in a manner and frequency sufficient to induce activation of innate and/or adaptive immune responses. In one embodiment the invention teaches administration of dendritic cells pulsed with one or more innate immune stimulants in a manner endowing said dendritic cell with ability to induce augmentation of natural killer (NK) cell number and/or activity. In another embodiment the invention teaches the use of dendritic cells stimulated with innate immune activators in a manner to allow for uptake of viral particles and presentation of viral epitopes to T cells in order to stimulate immunological activation and/or memory responses. | 2021-12-23 |
20210393682 | METHOD OF MODIFYING MACROPHAGE DIFFERENTIATION AND IMMUNITY - A method of treating a cancer, the method comprising: providing a genetically modified macrophage or monocyte that contains a nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the nucleic acid sequence is operably linked to a heterologous promoter and the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer. | 2021-12-23 |
20210393683 | METHODS OF MANAGING TUMOR FLARE IN ADOPTIVE IMMUNOTHERAPY - Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer's ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient. | 2021-12-23 |
20210393684 | Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases - Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and/or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and/or treatment of CMV infection, reactivation, and/or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients. | 2021-12-23 |
20210393685 | ANTI-CD33 AND NKG2D LIGAND CHIMERAS FOR TREATMENT OF MYELOID MALIGNANCIES - Disclosed herein are compositions and methods relating to fusion proteins that target a lineage-specific cell-surface antigen for treating hematological malignancies. | 2021-12-23 |
20210393686 | THERAPEUTIC AGENTS COMPRISING NUCLEIC ACIDS AND TCR MODIFIED IMMUNE CELLS AND USES THEREOF - A therapeutic agent comprising a nucleic acid and a TCR modified immune cell and use thereof. The therapeutic agent comprises a first composition comprising a first active ingredient and a second composition comprising a second active ingredient. The first active ingredient includes or contains a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell. The labeling polypeptide has one or more epitope polypeptides which can be presented on a surface of the tumor cell and/or cancer cell by MHC class I molecules. The second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier and the second active ingredient comprises a T cell receptor modified immune cell which can specifically recognize and bind to the epitope polypeptide presented by MHC class I molecules. The therapeutic agent achieves synergistic treatment effect and provides a new route for tumor treatment. | 2021-12-23 |
20210393687 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS - Provided herein are nucleic acids, vectors, and cells containing an expression-optimized codon that encodes a Munc13-4 polypeptide or a STXBP2 polypeptide. Also provided are methods of making and using the nucleic acids, vectors, and cells. Also provided herein are methods of treating of Hemophagocytic Lymphohistiocytosis (HLH) in a subject. | 2021-12-23 |
20210393688 | MODIFIED PDC LINE FOR SECRETING A CYTOKINE - The present invention relates to a genetically modified PDC (plasmacytoid dendritic cell) line for secreting a cytokine and to its use for increasing the expansion of antigen-specific cells in immunotherapies. | 2021-12-23 |
20210393689 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) - Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy. | 2021-12-23 |
20210393690 | METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN - Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy. | 2021-12-23 |
20210393691 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS - The present disclosure provides cell populations enriched for CD57 negative T cells, or depleted for CD57 positive cells, and methods for stimulating, cultivating, expanding, and/or genetically engineering cell populations enriched for CD57− T cells or depleted for CD57+ T cells. Also included are methods for generating, isolating, enriching, or selecting CD57− T cells or depleting CD57+ cells, such as by negative selection. | 2021-12-23 |
20210393692 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER - Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a SIRPα polypeptide. | 2021-12-23 |
20210393693 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof - The present disclosure provides T-cell modulatory multimeric polypeptides (T-Cell-MMP) and their epitope conjugates comprising at least one immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”). The epitope may be, for example, a cancer-associated epitope, an infectious disease-associated epitope, or a self-epitope. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for the IL-2R, to T-cells in an epitope selective/specific manner, and accordingly, for treating individuals with a cancer, infectious disease or autoimmune disorder. | 2021-12-23 |
20210393694 | Coordinating Gene Expression Using RNA Destabilizing Elements - Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. | 2021-12-23 |
20210393695 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES - Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided. | 2021-12-23 |
20210393696 | COMPOSITIONS FOR IMPROVING VACCINE SAFETY AND EFFICACY AND METHODS OF USE THEREOF - The present disclosure provides methods and compositions for reducing the incidence, severity, and/or duration of at least one sign of respiratory infection. The methods include the steps of administering a composition comprising gastrointestinal microbiota and an immunogenic composition to an animal in need thereof. | 2021-12-23 |
20210393697 | USE OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF INFLAMMATION - Provided are methods of determining whether a mammalian subject having an inflammatory condition (e.g., an oral inflammatory condition) will respond positively to mesenchymal stem cell (MSC) therapy, as well as method of treating such inflammatory conditions by administering MSCs. | 2021-12-23 |
20210393698 | METHODS FOR THE EXPANSION OF MESENCHYMAL STROMAL CELLS - Provided herein are methods for expanding populations of mesenchymal stromal cells (MSCs) comprising treating a population of MSCs derived from cord tissue with a pre-activation cytokine cocktail. Further provided herein are methods of treating immune disorders with the MSCs | 2021-12-23 |
20210393699 | FACTORS AND CELLS THAT PROVIDE FOR INDUCTION OF BONE, BONE MARROW, AND CARTILAGE - Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo. | 2021-12-23 |
20210393700 | INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF - The present disclosure is directed to systems, methods, and compositions for functional interaction of fibroblasts with one or more types of immune cells such that the interaction results in modification to the fibroblasts, the one or more types of immune cells, or both. In some embodiments, one or more certain agents are also utilized during the interaction or in lieu of one of the types of cells. In specific embodiments, cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity. | 2021-12-23 |
20210393701 | REGENERATIVE ABSCOPAL EFFECTS - Embodiments of the disclosure encompass methods and compositions using fibroblasts for stimulating regeneration in a first tissue site in an individual, comprising the step of administering at least one regenerative composition to a second tissue site, wherein the second tissue site comprises the same tissue type as the first tissue site in the individual. The first and second sites are at different locations in the individual, in particular embodiments. Particular embodiments comprise administering one or more compositions to an individual at a different anatomical site than the site that is in need, such as a joint. | 2021-12-23 |
20210393702 | METHODS OF TREATING CHRONIC WOUNDS WITH AMNIOTIC FLUID HAVING ELEVATED LEVELS OF TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES - Methods for treating chronic wounds with an amniotic fluid having a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are described. The amniotic fluid can be obtained from a female donor during a period of gestation when the concentration of endogenous TIMPs are at or near their maximum level. The methods described herein are particularly useful for promoting wound healing in chronic wounds having elevated protease activity, such as increased amounts or specific activity of matrix metalloproteinases. | 2021-12-23 |
20210393703 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising one or more bacterial strains for treating or preventing sensory hypersensitivity. | 2021-12-23 |
20210393704 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS - The present invention relates to | 2021-12-23 |
20210393705 | Engineered Therapeutic Probiotic System and Method - The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria ( | 2021-12-23 |
20210393706 | LACTOBACILLUS PARACASEI AO356 STRAIN HAVING ANTI-OBESITY ACTIVITY AND METHOD FOR PREVENTING, ALLEVIATING OR TREATING OBESITY USING THE SAME | 2021-12-23 |
20210393707 | SYSTEMS AND METHODS FOR TREATING A DYSBIOSIS USING FECAL-DERIVED BACTERIAL POPULATIONS - The present invention provides a method, wherein the method treats a subject having a dysbiosis, the method comprising: determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of: | 2021-12-23 |
20210393708 | EXTERNAL AGENT FOR HAIR GROWTH OR HAIR LOSS PREVENTION - The present invention relates to an external agent for growing hair or preventing hair loss comprising at least one member selected from the group consisting of cells of lactic acid bacteria belonging to the genus | 2021-12-23 |
20210393709 | PROBIOTIC COMPOSITION - A probiotic composition comprising | 2021-12-23 |